Skip to main
BMY

Bristol-Myers (BMY) Stock Forecast & Price Target

Bristol-Myers (BMY) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 21%
Buy 21%
Hold 50%
Sell 7%
Strong Sell 0%

Bulls say

Bristol-Myers Squibb's recent increases in probability of success (PoS) for key drug candidates, such as milvexian and the iber/mezi combination, signal a heightened confidence in their potential market performance, with risk-adjusted sales estimates rising substantially to $1.2 billion and $3.6 billion, respectively, for 2033. The company's robust pipeline and anticipated growth in products like Eliquis, alongside promising trends in their Growth Products, solidify a positive outlook on revenue prospects following guidance that exceeded market expectations. Additionally, strategic business development efforts and an emphasis on transforming its product portfolio contribute to a bullish sentiment regarding the company's long-term financial trajectory.

Bears say

Bristol-Myers Squibb's anticipated regulatory approval and launch delays for new products pose substantial risks to its revenue and earnings potential. Additionally, the company's forward EV/EBITDA multiple underperformance, at a level below the peer average of 11.2x, suggests that market confidence may be wavering. Compounding these concerns are the inherent risks associated with clinical trials, such as potential regulatory setbacks and competitive innovations that could diminish the relevance of new therapies.

Bristol-Myers (BMY) has been analyzed by 14 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 21% recommend Buy, 50% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bristol-Myers (BMY) Forecast

Analysts have given Bristol-Myers (BMY) a Buy based on their latest research and market trends.

According to 14 analysts, Bristol-Myers (BMY) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $61.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $61.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bristol-Myers (BMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.